
ObjectiveNon-alcoholic fatty liver disease (NAFLD) is characterized by growth hormone deficiency (GHd). We investigated the association between NAFLD and GHd in patients with nonfunctioning pituitary adenomas (NFPA).Design and methodsWe recruited patients with NFPA who underwent transsphenoidal adenectomy between January 2005 and December 2018. Pituitary function was determined by the insulin tolerance test, thyroid hormone assay, and gonadal hormone levels. NAFLD was defined as a hepatic steatosis index greater than 36.ResultsAmong 278 patients (mean age, 44.2 years; 58.6% [n=163] female), 103 (37.0%) had GHd, 139 (50.0%) had hypogonadism, and 75 (27.0%) had NAFLD. The prevalence of NAFLD was significantly higher in patients with GHd than in those without (36.9% vs. 21.1%, p=0.01). Even after adjusting for age, total cholesterol level, gonadal function, and prolactin level, patients with GHd had approximately two-fold higher prevalence of NALFD than those without GHd (adjusted odds ratio [OR]=1.85, 95% confidence interval [CI]=1.05–3.28, p=0.03). Among female patients, the prevalence of NALFD was significantly higher in those with GHd than in those without (adjusted OR=2.39, 95% CI=1.03–5.55, p=0.04); whereas, among male patients, the prevalence of NAFLD was statistically similar between those with and without GHd (p>0.05). In addition, gonadal function did not affect the prevalence of NAFLD in patients with NFPA (29.3% with eugonadism vs. 47.8% with hypogonadism, p=0.14).ConclusionAmong patients with NFPA, the prevalence of NAFLD was two-fold higher in patients with GHd than that in those without GHd. Thus, screening for NAFLD might be required in NFPA patients with GHd.
nonalcoholic fatty liver disease, growth hormone deficiency, Male, Adult, Adenoma, hepatic steatosis index, 610, Adenoma* / surgery, nonfunctioning pituitary adenoma, Diseases of the endocrine glands. Clinical endocrinology, Hypopituitarism, Adenoma* / complications, Endocrinology, Pituitary Neoplasms* / surgery, Non-alcoholic Fatty Liver Disease, Pituitary Neoplasms* / complications, 616, Humans, Pituitary Neoplasms, Pituitary Neoplasms* / epidemiology, Human Growth Hormone*, Non-alcoholic Fatty Liver Disease* / epidemiology, Hypogonadism* / complications, Hypogonadism* / epidemiology, Non-alcoholic Fatty Liver Disease* / complications, Hypopituitarism* / complications, Human Growth Hormone, Hypogonadism, RC648-665, growth hormone, Hypopituitarism* / epidemiology, Female, Adenoma* / epidemiology
nonalcoholic fatty liver disease, growth hormone deficiency, Male, Adult, Adenoma, hepatic steatosis index, 610, Adenoma* / surgery, nonfunctioning pituitary adenoma, Diseases of the endocrine glands. Clinical endocrinology, Hypopituitarism, Adenoma* / complications, Endocrinology, Pituitary Neoplasms* / surgery, Non-alcoholic Fatty Liver Disease, Pituitary Neoplasms* / complications, 616, Humans, Pituitary Neoplasms, Pituitary Neoplasms* / epidemiology, Human Growth Hormone*, Non-alcoholic Fatty Liver Disease* / epidemiology, Hypogonadism* / complications, Hypogonadism* / epidemiology, Non-alcoholic Fatty Liver Disease* / complications, Hypopituitarism* / complications, Human Growth Hormone, Hypogonadism, RC648-665, growth hormone, Hypopituitarism* / epidemiology, Female, Adenoma* / epidemiology
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 9 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
